367 related articles for article (PubMed ID: 17177422)
1. Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.
Lawhorn BG; Boga SB; Wolkenberg SE; Colby DA; Gauss CM; Swingle MR; Amable L; Honkanen RE; Boger DL
J Am Chem Soc; 2006 Dec; 128(51):16720-32. PubMed ID: 17177422
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.
Swingle MR; Amable L; Lawhorn BG; Buck SB; Burke CP; Ratti P; Fischer KL; Boger DL; Honkanen RE
J Pharmacol Exp Ther; 2009 Oct; 331(1):45-53. PubMed ID: 19592665
[TBL] [Abstract][Full Text] [Related]
3. Total synthesis and biological evaluation of the protein phosphatase 2A inhibitor cytostatin and analogues.
Bialy L; Waldmann H
Chemistry; 2004 Jun; 10(11):2759-80. PubMed ID: 15195307
[TBL] [Abstract][Full Text] [Related]
4. Fostriecin: chemistry and biology.
Lewy DS; Gauss CM; Soenen DR; Boger DL
Curr Med Chem; 2002 Nov; 9(22):2005-32. PubMed ID: 12369868
[TBL] [Abstract][Full Text] [Related]
5. Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition.
Buck SB; Hardouin C; Ichikawa S; Soenen DR; Gauss CM; Hwang I; Swingle MR; Bonness KM; Honkanen RE; Boger DL
J Am Chem Soc; 2003 Dec; 125(51):15694-5. PubMed ID: 14677930
[TBL] [Abstract][Full Text] [Related]
6. Cytostatin, an inhibitor of cell adhesion to extracellular matrix, selectively inhibits protein phosphatase 2A.
Kawada M; Amemiya M; Ishizuka M; Takeuchi T
Biochim Biophys Acta; 1999 Nov; 1452(2):209-17. PubMed ID: 10559474
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of cytostatin analogues.
Bialy L; Waldmann H
Chem Commun (Camb); 2003 Aug; (15):1872-3. PubMed ID: 12932009
[TBL] [Abstract][Full Text] [Related]
8. Total synthesis and evaluation of phostriecin and key structural analogues.
Burke CP; Swingle MR; Honkanen RE; Boger DL
J Org Chem; 2010 Nov; 75(22):7505-13. PubMed ID: 20669916
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric total synthesis of (+)-fostriecin.
Reddy YK; Falck JR
Org Lett; 2002 Mar; 4(6):969-71. PubMed ID: 11893198
[TBL] [Abstract][Full Text] [Related]
10. The potent protein phosphatase 2A inhibitors aminocytostatins: new derivatives of cytostatin.
Tohyama S; Kawada M; Muramatsu H; Hatano M; Inoue H; Matoba K; Sawa R; Igarashi M
J Antibiot (Tokyo); 2021 Oct; 74(10):743-751. PubMed ID: 34290381
[TBL] [Abstract][Full Text] [Related]
11. Total synthesis, assignment of the relative and absolute stereochemistry, and structural reassignment of phostriecin (aka Sultriecin).
Burke CP; Haq N; Boger DL
J Am Chem Soc; 2010 Feb; 132(7):2157-9. PubMed ID: 20108904
[TBL] [Abstract][Full Text] [Related]
12. Versatile enantiocontrolled synthesis of (+)-fostriecin.
Esumi T; Okamoto N; Hatakeyama S
Chem Commun (Camb); 2002 Dec; (24):3042-3. PubMed ID: 12536807
[TBL] [Abstract][Full Text] [Related]
13. Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.
Maki K; Motoki R; Fujii K; Kanai M; Kobayashi T; Tamura S; Shibasaki M
J Am Chem Soc; 2005 Dec; 127(48):17111-7. PubMed ID: 16316259
[TBL] [Abstract][Full Text] [Related]
14. Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.
Walsh AH; Cheng A; Honkanen RE
FEBS Lett; 1997 Oct; 416(3):230-4. PubMed ID: 9373158
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of Dehydro-Dephospho-Fostriecin and Formal Total Synthesis of Fostriecin.
Gao D; Li B; O'Doherty GA
Org Lett; 2019 Oct; 21(20):8334-8338. PubMed ID: 31584287
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of the protein phosphatase 2A inhibitor (4S,5S,6S,10S,11S,12S)-cytostatin.
Bialy L; Waldmann H
Angew Chem Int Ed Engl; 2002 May; 41(10):1748-51. PubMed ID: 19750704
[No Abstract] [Full Text] [Related]
17. Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.
Weinbrenner C; Baines CP; Liu GS; Armstrong SC; Ganote CE; Walsh AH; Honkanen RE; Cohen MV; Downey JM
Circulation; 1998 Sep; 98(9):899-905. PubMed ID: 9738645
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibitors of protein phosphatase 2A inhibit tumor metastasis through augmentation of natural killer cells.
Kawada M; Kawatsu M; Masuda T; Ohba S; Amemiya M; Kohama T; Ishizuka M; Takeuchi T
Int Immunopharmacol; 2003 Feb; 3(2):179-88. PubMed ID: 12586599
[TBL] [Abstract][Full Text] [Related]
19. Total synthesis of fostriecin: via a regio- and stereoselective polyene hydration, oxidation, and hydroboration sequence.
Gao D; O'Doherty GA
Org Lett; 2010 Sep; 12(17):3752-5. PubMed ID: 20687585
[TBL] [Abstract][Full Text] [Related]
20. Total synthesis of an antitumor antibiotic, Fostriecin (CI-920).
Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
J Am Chem Soc; 2003 Jul; 125(27):8238-43. PubMed ID: 12837094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
